Delving into the Latest Updates on Guselkumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Guselkumab (Genetical Recombination), Guselkumab (genetical recombination) (JAN), Guselkumab (USAN)

+ [7]

Target

IL-23p19

Action

inhibitors

Mechanism

IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesDigestive System Disorders+ [5]

Active Indication

Colitis, UlcerativeCrohn's disease, active moderateCrohn's disease, active severe+ [23]

Inactive Indication

Adenomatous Polyposis ColiCeliac DiseaseGeneralized Pustular Psoriasis+ [5]

Originator Organization

Janssen Global Services LLC

Active Organization

Janssen-Cilag International NVJanssen Scientific Affairs LLCJanssen Research & Development LLC

+ [9]

Inactive Organization-

License Organization

Janssen Pharmaceuticals, Inc.

Celsius Therapeutics, Inc.

MorphoSys AG

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (13 Jul 2017),

Plaque psoriasis

RegulationBreakthrough Therapy (China), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 9493545H

Source: *****

Sequence Code 9493571L

Source: *****

Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA) is considered the procedure of choice in patients with ulcerative colitis (UC) refractory to medical therapy or with neoplasia. The most common complication after IPAA is the development of pouchitis. Pouchitis is clinically characterized by variable symptoms including increased stool frequency, altered consistency, bloody stools, abdominal cramping, urgency, and incontinence. Symptomatic pouchitis longer than four weeks is considered chronic pouchitis.
The conventional treatment for acute and chronic pouchitis is antibiotics, such as metronidazole and ciprofloxacin. The disease course of antibiotic responsive pouchitis may evolve into antibiotic dependent (requiring antibiotic maintenance therapy) pouchitis and then antibiotic refractory (no response to antibiotic treatment) pouchitis. Although many patients respond to antibiotic therapy, there is also evidence that suggest that aberrant regulation of the mucosal immune system might play a part in the pathogenesis of pouchitis arising from an abnormal mucosal immune response to a dysbiosis of the pouch microbiota. If individuals fail to respond to antibiotics, anti-tumor necrosis factor (anti-TNF) agents and vedolizumab have been proposed for the treatment of chronic pouchitis.
Guselkumab, an interleukin-23 (IL-23) p19 subunit antagonist monoclonal antibody, is proven to be efficacious in patients with moderately-to-severely active UC. Efficacy of guselkumab in treating UC has been shown in multiple large clinical trials. However, patients with pouchitis were never the targeted population and were even often excluded from the trials.
Pouchitis becomes a chronic problem with a huge impact in the quality of life of these patients. The incidence of pouchitis has been rising in the last decades. This increase might be explained by a change in dietary habits of this population.
This open label single center trial at UZ Leuven aims to evaluate the efficacy and safety of guselkumab in the treatment of chronic antibiotic refractory pouchitis during a 48-week treatment period, with or without a dietary intervention. Twenty subjects with a proctocolectomy and IPAA for UC who have developed chronic or relapsing pouchitis will be enrolled.

Start Date30 Sep 2025

Sponsor / Collaborator-

NCT06586281

/ RecruitingNot ApplicableIIT

Elucidating Shared Mechanisms Contributing to Non-Alcoholic Fatty Liver Disease (NAFLD) and Psoriatic Arthritis (PsA) Disease Severity With Guselkumab Therapy

While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared disease mechanisms may explain the increased severity in PsA. This study involves two visits from PsA patients with NAFLD and active disease signs (e.g., swollen joint, enthesitis, or psoriatic plaque). It aims to assess the impact of biological therapies on liver disorders, joints, and skin in PsA patients.

Start Date01 Jun 2025

Sponsor / Collaborator

University of California San Diego

[+1]

NCT06651489

/ RecruitingPhase 2IIT

Efficacy of Guselkumab in the Treatment of Hailey Hailey Disease: An Open-label, Proof of Concept Study

Hailey-Hailey disease (HHD) is a debilitating genetic skin disorder, affecting mainly body folds with erythema and painful erosions and blisters. Histopathological findings include epidermal hyperplasia, suprabasilar clefting, dyskeratosis and acantholysis of keratinocytes. A final diagnosis of HHD is usually confirmed based on clinical and histopathological findings in line with genetic testing.
Several treatment options have been proposed for this chronic and disabling disorder, however, there is no reproducibly effective therapeutic for it.
The primary objective is to evaluate the treatment response of guselkumab. Single-center, non-randomized, single-arm, open-label, phase II trial to evaluate the efficacy and safety of guselkumab for the treatment of patients with HHD.

Start Date13 Mar 2025

Sponsor / Collaborator

Yale University

[+1]

100 Clinical Results associated with Guselkumab

Login to view more data

100 Translational Medicine associated with Guselkumab

Login to view more data

100 Patents (Medical) associated with Guselkumab

Login to view more data

806

Literatures (Medical) associated with Guselkumab

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis

Review

Author: Sun, YuanQiang ; Zhao, XiTong ; Li, WenChao ; Liu, Hong ; Zhang, LiHong

BACKGROUND:

Multiple biologics are available for psoriasis treatment, but switching treatments is often necessary at some point. The choice between intraclass or interclass biologic switching has not been extensively investigated.

METHODS:

Two independent authors searched the databases PubMed and EMBASE for studies reporting on biologic switching in psoriasis patients. Our study was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines.

RESULTS:

A total of 19 publications, comprising 679 patients, were included. The intraclass switching group consisted of 519 patients, while the interclass switching group included 139 patients. For intraclass switching, there are respectively 160, 326 and 33 patients switched of TNF-α, IL-17, IL-23. For interclass switching, 11 patients switched from TNF-α to IL-17, 6 from IL-17 to IL-23, 41 from IL-17 to IL-12/23, 29 from IL-17 to TNF-α, 15 from IL-12/23 to IL-17, 8 from IL-12/23 to IL-23. After 12 weeks, the proportion of patients achieving Psoriasis Area and Severity Index (PASI)75 was significantly higher in the intraclass switching group compared to the interclass switching group. However, after 16-52 weeks, the PASI75 proportions were comparable between the groups.

CONCLUSION:

Intraclass switching shows better short-term efficacy than interclass switching. However, in the long term, both switching strategies are effective and safe. This study also shows that adalimumab, ixekizumab, and risankizumab are the preferred agents for intraclass switching, whereas guselkumab serves as the primary agent for interclass transitions.

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe

Review

Author: Ständer, S. ; Thaçi, D.

Background: Psoriasis is a chronic inflammatory disease affecting about 2% of the global population, with moderate-to-severe forms requiring systemic treatment for successful disease management. By targeting the interleukin (IL)-23p19 subunit of IL-23, the master cytokine of psoriasis pathogenesis, guselkumab, tildrakizumab, and risankizumab offer improved risk-benefit profiles.Objective: While randomized clinical trials (RCTs) provide controlled data, real-world evidence (RWE) offers insights into the performance of these therapies in diverse patient populations, including those with comorbidities or difficult-to-treat areas affected. With RWE on these inhibitors constantly emerging, a comprehensive overview and expert interpretation are essential for providing key insights into psoriasis management in clinical practice.Methods: This review, therefore, examined RWE on the effectiveness and safety of IL-23p19 inhibitors compared to their pivotal RCTs.Results: Despite some gaps between RCT and RWE outcomes, particularly in underrepresented subpopulations, IL-23p19 inhibitors show strong effectiveness and favorable safety across both settings in the short- and especially in the long term, accompanied by an improvement in health-related quality of life and reduction of the main symptoms.Conclusion: Altogether, these factors make these medicines ideal treatment options. Future research should focus on improving patient-reported outcomes, specifically addressing psychological and quality-of-life aspects, to further optimize psoriasis management.

01 Dec 2025·IMMUNOLOGIC RESEARCH

Residual non-specific and disease-specific inflammatory markers in successfully treated young psoriasis patients: a cross-sectional study

Article

Author: Kraner Šumenjak, Tadeja ; Merzel Šabović, Eva Klara ; Božič Mijovski, Mojca ; Janić, Miodrag

Abstract:

Psoriasis is a chronic, immune-mediated disease. The systemic inflammation triggered by psoriasis contributes significantly to increased cardiovascular risk. While various treatments completely clear the skin, the associated effects on systemic inflammation are not yet clear. We investigated residual systemic inflammation in successfully treated patients. Circulating disease-specific and non-specific inflammatory markers were measured and compared in 80 psoriasis patients (aged 30–45 years) successfully treated with topical therapy, methotrexate, adalimumab, secukinumab or guselkumab, and in 20 healthy controls. Non-specific inflammatory markers (high-sensitivity C-reactive protein (hs-CRP), complete blood count (CBC) parameters, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume-to-platelet ratio (MPR), and red blood cell distribution width-to-platelet ratio (RPR)) and disease-specific inflammatory markers (interferon-γ (IFN-γ), tumor necrosis factor (TNF), interleukin (IL)-1β, IL-12p70, IL-17, and IL-23) were measured and compared between groups. Disease-specific cytokines (IFN-γ, TNF, IL-1β, IL-12p70, and IL-17, but not IL-23), were significantly elevated in patients compared to controls, while non-specific inflammatory markers showed no differences compared to controls. The residual disease-specific cytokines were similarly elevated in all five treated groups. In addition, they correlated significantly with body mass index (BMI) and waist circumference. Our results suggest that psoriasis patients have elevated residual disease-specific cytokines despite successful treatment, while the non-specific inflammatory markers are similar to those in control subjects. Residual disease-specific inflammatory markers correlated with BMI and waist circumference. A possible beneficial effect of body weight control in psoriasis patients merits further investigation. The study was registered at http://clinicaltrials.gov (identifier: NCT05957120) on July 24, 2023.

255

News (Medical) associated with Guselkumab

16 Jul 2025

·endpoints.news

Updated: J&J's Stelara faces continued biosimilar competition, with Q2 revenue falling 43%

Johnson & Johnson said revenue for its megablockbuster Stelara continued to decline in the face of emerging biosimilar competition. The company said Tuesday that global sales of Stelara were down 42.7% to $1.65 billion in the second quarter and dropped 38.6% in the first six months of 2024, compared to the same periods a year ago. The first biosimilar to Stelara was launched Jan. 1. Since then, at least five other competitors have entered the market. But J&J does not appear fazed. The company raised its sales guidance for the year to 3.2% to 3.7%, from 2% to 3% — increasing the midpoint by a full percentage point. It also said Darzalex and Tremfya continued to grow at a meaningful clip, with sales increasing by 21.7% and 25%, respectively, over the first six months of last year. J&J’s stock price $JNJ rose more than 4% in Wednesday morning trading. In an investor call, J&J executives said the raised guidance is due to strong growth from both the pharmaceuticals and medtech businesses. “If you take a look at the 90% of our business that is not Stelara, we actually had extraordinarily robust growth at 15.5%,” Jennifer Taubert, J&J’s pharmaceuticals chief, said on the call. “We’re really excited throughout the rest of this year because we’ve got a number of additional catalysts that are coming through with additional approvals and such.” Stelara sales were $3.3 billion in the first six months, down from $5.3 billion in the same period last year. In the first half, Darzalex sales were $6.8 billion, up from $5.6 billion, and Tremfya revenue increased to $2.1 billion, compared to $1.7 billion. First approved in 2009, Stelara was J&J’s top-selling drug before Darzalex overtook it last year. The company successfully delayed the emergence of Stelara competitors until 2025, and it’s using AbbVie’s Humira as a model for potential sales decline, though Humira did not face as much sales erosion in the first months competing against biosimilars. In its second-quarter earnings presentation, J&J reiterated that Humira’s “erosion curve remains the best proxy” for Stelara. Stelara’s annual revenue peaked in 2023 with $10.9 billion. J&J also noted that it expects to face headwinds from the Medicare Part D redesign taking place this year, which caps out-of-pocket spending at $2,000 and allows seniors to pay for prescription drugs monthly rather than all at once. Editor’s note: This article was updated with J&J’s stock movement and commentary from executives during the investor call.

Drug ApprovalBiosimilarFinancial Statement

16 Jul 2025

·www.biospace.com

J&J Targets $50B Oncology Sales By 2030: Updated

iStock, yuelan Johnson & Johnson’s $23.7 billion in second-quarter earnings, driven by cancer and neuroscience drugs, exceeded analyst expectations, while CEO Joaquin Duato set a target of $50 billion in oncology sales by 2030. Johnson & Johnson’s oncology and neuroscience units more than offset pressures on other parts of the business to drive medicine sales up 4.9%, the company reported Wednesday morning, with CEO Joaquin Duato setting an ambitious five-year target for the oncology division. The New Jersey–based pharma posted global sales of $23.7 billion and diluted earnings per share of $2.29. J&J’s medicine unit accounted for $15.2 billion of the sales, with medtech products contributing the other $8.5 billion. Both units beat the consensus estimate of analysts, Leerink Partners analysts said in a note to investors Wednesday morning, with medicine sales coming in 4% above expectations. Medicines and devices both contributed to the beat-and-raise quarter. Jennifer Taubert, worldwide chairman, innovative medicine at J&J, said on an investor call Wednesday morning that a broad set of products drove the pharma unit’s growth. “If you take a look at the 90% of our business that is not Stelara, we actually had extraordinarily robust growth of 15.5%, really demonstrating the strength across our portfolio,” Taubert said. “We had 13 brands that were growing double digits.” Oncology and neuroscience were the standout performers. In oncology, J&J reported 24% growth, fueled by market share gains for multiple myeloma blockbuster Darzalex, prostate cancer drug Erleada and CAR T cell therapy Carvykti. J&J named the launches of the bispecific antibodies Tecvayli, Talvey and Rybrevant as additional growth drivers. The company aims to grow oncology sales to $50 billion by 2030, Duato said on the call. J&J’s forecast is at least three times above the 2028 consensus, Taubert said, naming bladder cancer candidate TAR-200 as the asset with “the biggest disconnect between our internal forecasts and what the Street expects.” In neuroscience, rising demand for the depression drug Spravato helped J&J grow sales by 15.1% on a reported basis. The company grew neuroscience sales despite the Medicare Part D redesign and an unfavorable patient mix depressing sales of drugs including the atypical antipsychotic Invega Sustenna. In its Q2 presentation, J&J cited the Part D redesign as a headwind to multiple products, including its inflammatory disease drug Stelara. With Stelara also facing biosimilar competition, J&J said the product had an approximately 1,170 basis points (11.7%) impact on growth. Falling Stelara sales more than offset the growth of Tremfya and Simponi, causing immunology sales to fall 15.4%. The company expects Stelara biosimilar competition to accelerate in the second half of the year. Despite mounting pressure on the inflammatory disease drug, J&J raised its estimated reported sales growth for the full year. Previously, J&J forecast growth of 2.6% to 3.6%. Now, the company is targeting reported growth of 5.1% to 5.6% based on its strong performance in the quarter, CEO Joaquin Duato said on an investor call Wednesday morning. The change added $2 billion to the midpoint of J&J’s full-year sales estimate. Editor’s note: This story was updated with additional commentary from J&J’s earnings call.

16 Jul 2025

·www.biopharmadive.com

J&J absorbs Stelara, tariff hits to deliver beat-and-raise quarter

Johnson & Johnson on Wednesday reported quarterly prescription drug sales that for the first time surpassed $15 billion, highlighting the strength of the pharmaceutical companys portfolio during a year in which its formerly top-selling drug lost market exclusivity.Second quarter sales for J&Js pharmaceuticals business reached $15.2 billion between April and June, nearly 4% higher than the same period last year on an operational basis. Overall second quarter sales were up 4.6% on the same basis to total $23.7 billion, beating Wall Street forecasts.J&J now expects higher operational growth for 2025, increasing the midpoint of its guidance range for both adjusted sales and earnings per share.The company also halved its estimates for how much U.S. tariffs would weigh on its business this year. It now anticipates a roughly $200 million hit, exclusively within its medical device unit. President Donald Trump has said further levies on pharmaceuticals are coming soon, but indicated the duties would be phased in, potentially giving drugmakers time to adjust their operations and stockpile inventory.J&J shares jumped by more than 6% Wednesday morning following its earnings release.No other healthcare company has grown through the loss of exclusivity of a multibillion-dollar product in the first year, in our case Stelara, J&J CEO Joaquin Duato said on a conference call with analysts, referring to the companys 16-year-old psoriasis and inflammatory bowel disease medicine.Stelara sales during the quarter fell by 43% year over year, to $1.7 billion.J&J has a newer drug, Tremfya, that it has positioned as a successor to Stelara in many of the same diseases and hopes will eventually grow into a $10 billion-a-year product. Sales in the second quarter rose 30% year over year to $1.2 billion as more doctors prescribed it for Crohns disease and ulcerative colitis.But its J&Js oncology business thats providing the most significant counterweight to Stelaras loss of exclusivity. Overall cancer drug sales were $6.3 billion between April and June, more than $1 billion higher than in the same period last year.Over half of that total came from J&Js multiple myeloma medicine Darzalex, which is one of several drugs the company sells for the blood cancer. Duato claimed about 80% of all multiple myeloma patients receive a J&J therapy as some point in their treatment.By the end of the decade, J&J predicts its oncology business will bring in $50 billion in annual sales, notably higher than what analysts on Wall Street currently estimate.Jennifer Taubert, head of the companys pharmaceuticals business, pointed to Darzalex and its multiple myeloma cell therapy Carvykti as key contributors to that goal. Two other J&J medicines, Tecvayli and Talvey, are also approved for the blood cancer, but are early in their respective launches.Taubert also highlighted a drug-device combination called TAR-200 that J&J is targeting for use in non-muscle invasive bladder cancer. That is probably the asset that has the biggest disconnect between our internal forecasts and what the Street expects, she said. If you take a look at 2028 consensus, we actually see our numbers at least three times higher.J&J previously detailed several other drugs for which analysts forecasts diverge from its own. One other is a combination of the medicines Rybrevant and Lazcluze, which are approved for a certain type of metastatic lung cancer. The company aims to win U.S. clearance for a subcutaneous version of Rybrevant, but had its application rejected by the Food and Drug Administration in December.On Wednesdays call, Taubert said the agencys complete response letter related to a manufacturing question or two and J&J has since responded. '

Drug ApprovalCell Therapy

100 Deals associated with Guselkumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10438	Guselkumab	L04AC16	DB11834

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Colitis, Ulcerative	Japan	Janssen Pharmaceutical KK	27 Mar 2025
Crohn's disease, active moderate	China	Janssen-Cilag International NV	20 Feb 2025
Crohn's disease, active severe	China	Janssen-Cilag International NV	20 Feb 2025
Ulcerative colitis, active moderate	United States	Janssen Biotech, Inc.	11 Sep 2024
Ulcerative colitis, active severe	United States	Janssen Biotech, Inc.	11 Sep 2024
Pustulosis of Palms and Soles	Japan	Janssen Pharmaceutical KK	21 Nov 2018
Erythrodermic psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Pustular psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Arthritis, Psoriatic	European Union	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Iceland	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Liechtenstein	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Norway	Janssen-Cilag International NV	10 Nov 2017
Plaque psoriasis	United States	Janssen Biotech, Inc.	13 Jul 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Juvenile Idiopathic Arthritis	NDA/BLA	United States	Johnson & Johnson	02 Dec 2024
Crohn Disease	NDA/BLA	China	Xian-Janssen Pharmaceutical Ltd.	06 Mar 2024
Pediatric Crohn's Disease	Phase 3	United States	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Japan	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Austria	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Belgium	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Brazil	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Canada	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	France	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Israel	Janssen Research & Development LLC	13 Mar 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05272150 (VISIBLE study, Pubmed \| JAMA Dermatol)	Phase 3	Psoriasis	103	Guselkumab 100 mg	udsgfzgbnt(mfqyzzlcld) = Infections were the most common adverse events in the guselkumab (16 [20.8%]) and placebo (3 [11.5%]) groups through week 16, predominantly upper respiratory tract infection and nasopharyngitis hwzkcqsevm (cahsipbalp )	Positive	25 Jun 2025
				Placebo
NCT05272150 (VISIBLE trial, Pubmed \| JAMA Dermatol)	Phase 3	Psoriasis of scalp	108	Guselkumab 100 mg	edmaoxevti(gcofajbqjh) = jioslipydh zkiupuwqgz (vlobcjvuqk ) View more	Positive	25 Jun 2025
				Placebo	edmaoxevti(gcofajbqjh) = hwzqrcooij zkiupuwqgz (vlobcjvuqk ) View more
NCT04397263 (CTgov)	Phase 3	Crohn Disease	38	Guselkumab	pdwzasmyuz = fehvptouuz gpcpwquypf (xwgnjndpel, fsgqzlupwc - crdsvivptk) View more	-	20 May 2025
NCT05528510 (ASTRO, PRNewswire \| Company_Website) Manual	Phase 3	Ulcerative colitis, active moderate \| Ulcerative colitis, active severe	418	TREMFYA® 100 mg q8w	hfhywjuskn(svrywyahld) = zapljdhgyx evmgduwtci (eqalwuycuj ) View more	Positive	05 May 2025
				TREMFYA® 200 mg q4w	hfhywjuskn(svrywyahld) = uyjmxhnydo evmgduwtci (eqalwuycuj ) View more
NCT04033445 (QUASAR, Company_Website) Manual	Phase 2/3	Colitis, Ulcerative	-	TREMFYA	qmnepnenvh(ihaopvzsne) = whwnqxyehn bkgzdcncoe (jwncyugmpq ) View more	Positive	05 May 2025
NCT04882098 (APEX, NEWS) Manual	Phase 3	Arthritis, Psoriatic	-	guselkumab	zpxuggzyob(ktfptncudg) = 达到了主要终点 ejwgukcuws (vbglvxamjt ) Met View more	Positive	07 Apr 2025
				Placebo
FDA_CDER Manual	Not Applicable	Crohn Disease	-	Placebo	hhnihakxrp(qrrsjdcgua) = lmnspradtm ousiiqdrdd (icmepkrige ) View more	Positive	20 Mar 2025
				TREMFYA 400 mg Subcutaneous Injection at Weeks 0, 4, and 8	hhnihakxrp(qrrsjdcgua) = piybhqpgjy ousiiqdrdd (icmepkrige ) View more
NCT03466411 (FDA_CDER) Manual	Phase 2/3	Crohn Disease	721	Placebo (CD1)	tsbctdyrfn(brjyienirz) = wjpshabcvz vixqbulebx (lilvmgoftz ) View more	Positive	20 Mar 2025
				TREMFYA 200 mg Intravenous Infusion (CD1)	tsbctdyrfn(brjyienirz) = ijxtfwscfd vixqbulebx (lilvmgoftz ) View more
NCT03451851 (PROTOSTAR, Pubmed \| Br J Dermatol)	Phase 3	Plaque psoriasis interleukin (IL)-23	-	Guselkumab	ffbvfnjonp(gokksklqxm) = ssqklhuzmn nezxqakvub (cfnijhkzbt ) View more	Positive	18 Mar 2025
				Placebo	ffbvfnjonp(gokksklqxm) = mlefhxuzoy nezxqakvub (cfnijhkzbt ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data